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Summary
Mutations in DNA mismatch repair (MMR) genes cause hereditary nonpolyposis colorectal cancer (HNPCC), and MMR
defects are associated with a significant proportion of sporadic cancers. MMR maintains genome stability and suppresses
tumor formation by preventing the accumulation of mutations and by mediating an apoptotic response to DNA damage.
We describe the analysis of a dominant MSH6 missense mutation in yeast and mice that causes loss of DNA repair function
while having no effect on the apoptotic response to DNA damaging agents. Our results demonstrate that MSH6 missense
mutations can effectively separate the two functions, and that increased mutation rates associated with the loss of DNA
repair are sufficient to drive tumorigenesis in MMR-defective tumors.
Introduction (MSI) indicative of a MMR defect (Peltomaki, 2003). The majority
of these HNPCC cases are due to inherited mutations in two
DNA mismatch repair (MMR) functions to repair misincorpora- MMR genes, MSH2 and MLH1 (Peltomaki, 2003; Yan et al.,
tion errors that occur during DNA replication and acts on mis- 2000). A small number of HNPCC cases are due to inherited
paired bases formed in recombination intermediates (Buer- mutations in MSH6, whereas a larger number of later onset
meyer et al., 1999; Kolodner, 1996; Kolodner and Marsischky, familial atypical-HNPCC cases are due to mutations in MSH6
1999; Modrich and Lahue, 1996). As a consequence of the role (Akiyama et al., 1997; Berends et al., 2002; Kolodner et al.,
1999; Miyaki et al., 1997). Sporadic MMR-defective cancers areof MMR in DNA replication, MMR-defective cells have high
mutation rates. MMR acts to prevent recombination between largely due to somatic silencing of the MLH1 gene (Kane et al.,
1997; Veigl et al., 1998). Defects in other MMR genes have beendivergent DNA sequences, and as a consequence, MMR may
also act to prevent some types of genome rearrangements (Ev- implicated in no more than a small proportion of inherited and
sporadic cancers. These differences between MMR genes haveans and Alani, 2000; Harfe and Jinks-Robertson, 2000; Myung
et al., 2001). MMR proteins also play a role in some cellular been attributed to the fact that some MMR proteins have unique
functions in MMR, whereas others play partially redundant rolesresponses to DNA damage, and consequently, MMR-defective
mammalian cells are resistant to killing by DNA-damaging (Harfe and Jinks-Robertson, 2000; Kolodner and Marsischky,
1999; Marsischky et al., 1996). However, some MMR proteinsagents, including some types of chemotherapeutic agents (Aebi
et al., 1996; Bignami et al., 2003; D’Atri et al., 1998; Li, 1999; could have different functions, such as, for example, a unique
role in DNA damage responses.Modrich, 1997). MMR defects can underlie the development of
cancer. HNPCC is an inherited cancer susceptibility syndrome Mouse models have provided insight into the relationship
between MMR defects and cancer susceptibility (Buermeyer etwhere, in many cases, the tumors show microsatellite instability
S I G N I F I C A N C E
Tumors that develop in HNPCC patients or sporadic cancers associated with MMR deficiency show increased genomic instability,
which can be diagnosed by microsatellite instability (MSI) analysis, and also display resistance to a wide variety of chemotherapeutic
agents. A substantial number of HNPCC cases result from missense mutations in MMR genes; however, the functional consequences
of such mutations in normal and tumor cells are not well understood. By modeling a human MSH6 missense mutation in yeast and
mice, we demonstrate that MMR missense mutations can differentially affect individual MMR functions. Our results provide new
molecular insights into the anticancer functions of MMR and indicate that genotype-phenotype correlations can provide valuable
information for the diagnosis and treatment of tumors with MMR mutations.
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al., 1999; Wei et al., 2002). Mice that are homozygous for null deletion mispairs and accounts for the dominant phenotypes
caused by these msh6 mutations (Hess et al., 2002).mutations in Msh2 or Mlh1 develop a broad spectrum of tumor
Currently, there are two views on how MMR defects leadtypes at early ages, and these tumors show MSI; in many re-
to increased development of cancer. In one view, increasedgards, these mice mimic HNPCC caused by MSH2 and MLH1
mutation rates increase the rate of accumulation of mutationsmutations (de Wind et al., 1998; Edelmann et al., 1999; Prolla
in tumor suppressor genes and protooncogenes, which resultset al., 1998; Reitmair et al., 1996). Mice that are homozygous
in the development of cancer (Kinzler and Vogelstein, 1996;for Msh6 mutations are similar to Msh2 and Mlh1 mutant mice
Loeb, 2001). In the other, defects in DNA damage responsesin regard to tumor spectrum. However, the Msh6 mutant mice
and DNA damage-induced apoptosis provides a selective ad-develop cancers at later ages, and the tumors show little or no
vantage to tumor cells (Fishel, 2001; Nowell, 1976; TomlinsonMSI (Edelmann et al., 1997). Studies of Msh6 mutant mice were
and Bodmer, 1999). To gain insight into these two possiblethe first to implicate MSH6 as a late onset cancer susceptibility
mechanisms, we have investigated the properties of specificgene, a result that has been extended to human populations.
single nucleotide changes in MSH6 in S. cerevisiae and mousePms2 defects in mice cause the development of tumors with
models. We describe a dominant mouse Msh6 mutation thatMSI at early ages, although the tumor spectrum is distinct from
causes a strong mutator phenotype and increased cancer devel-that of Msh2, Msh6, or Mlh1 mutant mice (Baker et al., 1995).
opment, but no defect in DNA damage-induced apoptosis, andThis difference in tumor spectrum correlates with the limited
provide evidence for such mutations in humans. These resultsinvolvement of PMS2 defects in HNPCC. Mutations in Msh3
indicate that the increased mutation rates resulting from MMRand Exo1 only cause the development of tumors at very old
defects are capable of driving the development of cancer, andages, which parallels the limited involvement of these genes in
that certain heterozygous MMR missense mutations can act in aHNPCC. However, Msh3 mutations accelerate the development
dominant negative manner to increase mutation rates in normalof tumors when combined with Msh6 mutations, similar to the
tissue.interaction between msh6 and msh3 mutations in S. cerevisiae
(de Wind et al., 1999; Edelmann et al., 2000; Kolodner et al.,
Results1999; Marsischky et al., 1996; Sia et al., 1997; Wei et al., 2003).
Mismatch recognition in eukaryotic MMR involves three pro-
Analysis of MSH6 missense mutations in S. cerevisiaeteins, MSH2, MSH6, and MSH3, which are homologs of the
Previous studies described three dominant mutations in thebacterial MutS protein. These three proteins form two hetero-
S. cerevisiae MSH6 gene that cause high rates of both base
dimeric complexes, the MSH2-MSH6 and MSH2-MSH3 com-
substitution and frameshift mutations, in contrast to an msh6
plexes, that each have different mismatch recognition properties
deletion mutation, which only causes high rates of base substitu-
(Acharya et al., 1996; Drummond et al., 1995; Genschel et al., tion mutations. Two of the affected amino acids (S. cerevisiae
1998; Guerrette et al., 1998; Marsischky et al., 1996; Palombo codons Ser1036 and Gly1142) are conserved in the human and
et al., 1995). The MSH2-MSH6 complex is the major mismatch mouse MSH6 proteins, whereas in one case, Gly1067Asp, the
recognition complex and recognizes both base:base and single amino acid at the equivalent residue in the human and mouse
base insertion/deletion mismatches, whereas the MSH2-MSH3 protein is a Thr (residues 1219 and 1217, respectively). Although
complex appears to primarily recognize insertion/deletion mis- the Gly1067Asp substitution is not located in the P loop domain,
matches. This difference is also reflected in their relative abun- which is required for ATP binding and processing, molecular
dance with MSH2-MSH6 complexes occurring in excess of modeling indicates that it is situated at the MSH2-MSH6 hetero-
MSH2-MSH3 complexes in yeast, human, and mouse (Mar- dimer interface close to the P loop of the MSH2 protein (Hess
sischky et al., 1996; Genschel et al., 1998; de Wind et al., 1999). et al., 2002). A recent study reported an MSH6 mutation causing
It is this difference in mismatch recognition spectrum that has a Thr to Ile change at codon 1219 in an HNPCC case with
been suggested to underlie the genetic differences between a tumor with MSI, although little information was presented
MSH2, MSH6, and MSH3 (Marsischky et al., 1996; Umar et al., supporting the pathogenic effects of this mutation (Berends et
1998). When the MSH complexes bind a mismatch, they form al., 2002). To study the affect of the Thr and Ile residues on
a ring around the DNA, and upon ATP binding, this ring can MSH6 function, mutations altering S. cerevisiae MSH6 codon
move along the DNA away from the mismatch (Blackwell et al., 1067 to either a Thr or Ile codon were studied both on an ARS
1998; Gradia et al., 1999; Hess et al., 2002). The importance of CEN plasmid and at the chromosomal MSH6 locus. On an ARS
the ATP binding-mediated release from mispairs has been in CEN plasmid in a wild-type strain, the wild-type MSH6 control
part established by the isolation of dominant mutations in MSH6 and the 1067Thr substitution did not alter the rate of reversion
in yeast (Das Gupta and Kolodner, 2000). These mutations of the lys2-A10 frameshift mutation (detects deletions in a run
strongly interfere with MMR when present on a single copy of 10 As), whereas the 1067Ile substitution caused a large in-
plasmid in a wild-type strain. At the chromosomal locus, they crease in mutation rate seen in a patch test (Figure 1A). Similar
cause high rates of base substitution and frameshift mutations, results were obtained using the CAN1 forward mutation assay
in contrast to only high rates of base substitution mutations (detects gene-inactivating frameshift and base substitution mu-
caused by MSH6 deletion mutations, and the increased rate of tations) and the hom3-10 frameshift reversion assay (detects
frameshift mutations is suppressed by overexpression of MSH3. deletions in a run of 7 Ts) (data not shown). When these plasmids
The mutant MSH2-MSH6 complexes hydrolyze ATP in the ab- were tested for their ability to complement an msh6 msh3 double
sence of DNA, but have a much longer half-life bound to a mutant, the wild-type MSH6 control and the MSH6 1067Thr
mispair in the presence of ATP than the wild-type complex; the substitution reduced the rate of reversion of the hom3-10
reduced turnover from mispairs may be responsible for pre- frameshift mutation similarly, whereas the vector and the MSH6
1067Ile substitution had no effect (Figure 1B). Similar resultsventing MSH2-MSH3 dependent MMR from acting on insertion/
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and highly predisposed to the development of tumors. The tu-
mor spectrum in these mice resembles that of MMR-deficient
human patients and includes lymphoid tumors, gastrointestinal
tumors, and tumors of the skin. Msh6 deficiency causes a defect
in the repair of base substitution mutations, but not of 2 bp
insertion/deletion mutations. Consequently, the tumors derived
from these mice do not display an MSI phenotype. However, a
large proportion of MSH6 mutations in human patients represent
missense mutations, whose functional consequences remain
unknown (Berends et al., 2002; Kolodner et al., 1999; Wijnen
et al., 1999; Wu et al., 1999). We therefore created a mouse
line carrying the Msh6T1217D mutation to assess the effect of an
Msh6 missense mutation on MMR function and cancer suscepti-
bility (Figures 2A and 2B); the Msh6T1217D allele is referred to as
Msh6TD throughout the manuscript. The Msh6TD allele is transmit-
ted in a normal Mendelian ratio, and both heterozygous and
homozygous mutant mice develop normally. RT-PCR and West-
ern blot analysis showed that the Msh6TD mutation did not inter-
fere with normal gene expression or the stability of the mutant
protein (Figures 2C and 2D). In human cells, MSH6 forms a
complex with MSH2 to initiate the repair of mispairs, and loss
of MSH6 affects the stability of the MSH2 protein (de Leeuw et
al., 2000; Palombo et al., 1995). Consistent with this, we de-
tected a reduction of Msh2 protein in Msh6/ MEF cells. How-
ever, we did not detect a similar reduction in the Msh2 protein
Figure 1. Genetic analysis of msh6 mutations in yeast levels in Msh6TD/ or Msh6TD/TD cell extracts, indicating that the
mutation had no effect on the stability of Msh2 protein (FigureA: The indicated plasmids were transformed into the wild-type strain RDKY
3686, and the presence of a dominant mutator phenotype was detected 2D). Immunohistochemical analysis also showed that the sub-
by determining the relative rate of reversion of the lys2::InsE-A10 allele by cellular distribution of the mutant Msh6TD or Msh2 protein was
replica plating the strains onto SD plates lacking lysine.
not affected (data not shown).B: The indicated plasmids were transformed into the RDKY 4234 msh6::hisG
msh3::hisG strain, and complementation of the msh6::hisG mutation was
detected by determining the relative rate of reversion of the hom3-10 allele Mismatch repair activities in Msh6TD mutant extracts
by replica plating the strains onto SD plates lacking threonine. We next analyzed the effect that the mutant Msh6TD protein had
C: Fluctuation analysis was used to determine the hom3-10 reversion rate on mismatch recognition and repair in ES cell extracts. Using
and the CAN1 forward mutation rate of the indicated strains. The numbers
gel mobility shift assays, we found that extracts of Msh6TD/given are the mutation rate followed by the fold increase in mutation rate
and Msh6TD/TD embryonic stem cells contained a G•T mismatchrelative to the wild-type rate in parentheses.
binding activity that was similar to that observed in Msh6/
extracts (Figure 3A); the activity present in all of the extracts
also bound homoduplex DNA, albeit to a lower extent. However,
were obtained using the CAN1 forward mutation assay and the
in contrast to Msh6/ extracts, the G•T binding activity presentlys2-A10 frameshift reversion assay (data not shown). Finally,
in both Msh6TD/ and Msh6TD/TD extracts was resistant to ATP-the MSH6 1067Asp, Thr, and Ile substitutions were introduced
dependent mismatch release, even at high ATP concentrationsat the chromosomal MSH6 locus and tested for their effects on
(see Figure 3A). These results are consistent with previous stud-the CAN1 forward mutation rate and the hom3-10 frameshift
ies of the corresponding msh6 mutation in yeast and indicatemutation reversion rate (Figure 1C). The MSH6 1067Thr substi-
that the mutant Msh2-Msh6TD complex displays a defect in thetution did not significantly increase the mutation rate in either
modulation of mispair binding and dissociation by ATP (Hessassay compared to the wild-type strain. In contrast, the MSH6
et al., 2002).1067Asp and MSH6 1067Ile substitutions had essentially the
To determine the impact of the Msh6TD mutation on DNAsame effect and increased the hom3-10 frameshift reversion
repair, we measured the in vitro DNA mismatch repair activityrate 8- to 10-fold more that the msh6 deletion mutation, and
in ES cell extracts using a variety of substrates containing G•Gincreased the CAN1 mutation rate about 2-fold more than the
mismatches, single-base insertion, or two-base insertion mis-msh6 deletion mutation; these mutation rates are about 50% of
matches with a nick either 5 or 3 to the mismatched basethat seen in an msh2 deletion mutant. These results demonstrate
(Figure 3B). The Msh6/ and Msh6TD/ extracts were proficientthat substituting a Thr for Gly1067 has no effect on MSH6
in the repair of all substrates tested, whereas the Msh6TD/TDfunction, whereas substitution of an Ile at this residue results
extracts did not repair any of these substrates. The repair defectin loss of MSH6 function and a strong dominant defect in the
in the Msh6TD/TD extracts differs from the defect previously foundrepair of frameshift mutations as observed for the original domi-
in Msh6/ extracts, which are defective in the repair of base-nant msh6 mutations.
base mismatches but not single-base insertion and dinucleotide
insertion mispairs (Edelmann et al., 1997, 2000). Furthermore,Generation of Msh6T1217D mutant mice
addition of increasing amounts of Msh6TD/TD extracts to Msh6/We previously generated a mouse line carrying an Msh6 null
allele (Msh6) (Edelmann et al., 1997). Msh6/ mice are viable extracts inhibited the repair of dinucleotide insertion mutations
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Figure 2. Generation of Msh6T1217D mice
A: Gene targeting strategy for the generation of Msh6T1217D mice, showing the pMsh6T1217D knockin targeting vector and the wild-type and targeted
genomic Msh6 locus before and after Cre-loxP-mediated deletion of the resistance cassette.
B: Representative Southern blot analysis of NdeI-digested tail genomic DNA from Msh6 wild-type (WT), heterozygous (TD/), homozygote (TD/TD), and
heterozygote undeleted (TDhyg/) mice.
C: RT-PCR analysis of total RNA isolated from Msh6 wild-type (WT), heterozygous (TD/), and homozygous (TD/TD) mutant ES cells. The TD mutation creates
an SfaNI site in the mutant transcript. The RNA transcript in WT mice is resistant to SfaNI digestion (246 bp fragment), while the mutant transcripts in TD/
and TD/TD mice can be digested into 221 bp and 25 bp (not shown) restriction fragments. The presence of the TD mutation in the RT-PCR products of
Msh6TD/ and Msh6TD/TD mice was further verified by DNA sequencing.
D: Western blot analysis shows expression of stable Msh2 and Msh6 protein in WT, heterozygous (TD/), and homozygous (TD/TD) mutant MEF cell extracts,
while no Msh6 protein and reduced amounts of Msh2 is detected in Msh6-deficient (/) extracts.
compared to control assays, in which the same amounts of In vivo mutation frequencies and spectra in Msh6
Msh6/ extracts were added to Msh6/ extracts (data not mutant mice
shown). These results demonstrate that in homozygous mutant The analysis of MSI only allows the detection of insertion/dele-
extracts, the mutant Msh6TD protein interferes with the ability of tion mutations and might not reflect all of the features of the
Msh2-Msh3 complexes to act in repair of dinucleotide insertion/ mutator phenotype in the Msh6 mutant mice. Therefore, we
deletion mutations. analyzed the mutation frequency at the cII locus in spleenocytes
using the Big Blue transgene system, which allows the analysis
of insertion/deletion mutations and base substitutions (AndrewMicrosatellite instability in Msh6TD mutant mice
et al., 2000; Kohler et al., 1991). There was a significant increaseThe repair defect observed in Msh6TD/TD cell extracts suggested
in mutation frequency in the Msh6TD/TD mice and also to a slightlythat the in vivo mutator phenotype in Msh6TD mutant mice would
lesser extent in the Msh6/ mice (Figure 5A). The differencediffer from wild-type and also Msh6 mice. To assess this, the
between Msh6TD/TD and Msh6/ was significant (p  0.0001).MSI phenotype was analyzed in tail genomic DNA of Msh6/,
Interestingly, this analysis also revealed a 2- to 3- fold increaseMsh6/, Msh6TD/, and Msh6TD/TD mice at a mononucleotide
in the mutation frequency in Msh6TD/ mice as compared torepeat locus (U12235) and two dinucleotide repeat loci (D7Mit91
wild-type mice (p  0.0001), which was not observed in theand D17Mit123) (Figures 4A and 4B). The Msh6TD/TD mice dis-
Msh6/ mice.played a significant increase in MSI at all three loci as compared
The analysis of the mutation spectra showed that the muta-to Msh6/mice (Figure 4B). The increase in MSI in the Msh6TD/TD
tions in Msh6/, Msh6/, and Msh6/ mice were predomi-was also significant compared to the MSI observed in Msh6/
nantly base substitutions, with a majority of mutations beingmice. In addition, the MSI at these loci in Msh6TD/TD was compara-
transitions and only some transversions (Figure 5B). The muta-ble to the MSI previously found in Mlh1/ mice (Wei et al.,
tion spectrum in Msh6TD/ mice largely resembled the spectrum2003). Interestingly, we also noted a significant increase in MSI
found in wild-type or Msh6 null mutant mice. In contrast, inin Msh6TD/ mice at the U12235 locus as compared to wild-type
Msh6TD/TD mice, almost half of the mutations were single basemice. The increase in MSI in Msh6TD/ mice at the D7Mit91
deletions or insertions. The difference between the mutationlocus was of borderline significance and not significant at the
spectra in Msh6TD/TD and Msh6/ or Msh6/ mice is highlyD17Mit123 locus as compared to wild-type mice. These results
significant (p values  0.0001), and indicates that the Msh6TDdemonstrate that the Msh6TD mutation results in a significant
MSI phenotype. mutation interferes with the repair of insertion/deletion mispairs.
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spectra in 12 mice that were between 7 and 14 months of age.
This showed that similar to Msh6/ mice, the majority of Msh6TD/TD
mice had developed B or T cell non-Hodgkin’s lymphomas (11/
12 mice) (Figures 7A and 7B) (Edelmann et al., 1997). We also
found tumors in the small intestines of the mice, including tubu-
lar adenomas (2/12 mice), a tubulovillous adenoma (1/12 mice),
and focal areas of dysplasia (4/12 mice) (Figure 7C). Some of
the mice also developed basal cell carcinomas of the skin (2/
12). We analyzed several of the tumors for the presence of
Msh6TD protein either by immunohistochemical analysis (Figure
7D) or Western blot analysis of microdissected tumor tissue
(not shown). We found that in all tumors (n  4) that were
analyzed, Msh6TD protein could readily be detected. Similarly,
immunohistochemical analysis of intestinal tumors showed that
while Msh3 was absent in the tumor cells in Msh3/ mice (Figure
7E), Msh3 could readily be detected at normal levels in the
tumor cells in Msh6TD/TD mice (Figure 7F).
To assess whether the reduction in survival of Msh6TD/ mice
was associated with increased tumorigenesis, we sacrificed 11
Msh6TD/ mice and 10 Msh6/ littermates that were still alive
between 17 and 22 months of age. A majority of Msh6TD/ mice
had developed non-Hodgkin’s lymphoma (7/11 mice) at this
age, while none of the wild-type mice had detectable tumors.
This analysis did not include the Msh6TD/ mice that had died
previously, and therefore is probably an underestimate of the
tumor phenotype. Some of the tumors in the heterozygous mice
were also analyzed for the status of the wild-type Msh6 allele
Figure 3. Mismatch repair activities in Msh6 mutant cell extracts by loss of heterozygosity (LOH) analysis. This showed that in
A: Mismatch binding activities of Msh6/, Msh6TD/, and Msh6TD/TD nuclear all tumors (n  5) tested, the wild-type allele was retained,
extracts. Gel mobility shift assay in Msh6 mutant nuclear extracts was per- indicating that tumor formation in Msh6TD/ mice is not associ-
formed by incubating nuclear protein extracts isolated from Msh6/ (/), ated with LOH at the wild-type allele (data not shown).Msh6TD/ (TD/), and Msh6TD/TD (TD/TD) ES cells with either GC-containing
The MMR defect observed in Msh6TD/TD extracts and thehomoduplex or G/T-containing heteroduplex oligonucleotides. The position
of the MutS-DNA complex and the unbound free probe are indicated mutator phenotype observed in normal tissue of Msh6TD mutant
by the arrows. Unlabeled (cold) G/T-containing heteroduplex competitor mice suggested the tumors in Msh6TD mice would show MSI.
oligonucleotide or ATP was included in the reaction mixture in the molar Indeed, we found that tumors in both Msh6TD/TD homozygous
ratio or concentration indicated.
and Msh6TD/ heterozygous mice displayed an MSI phenotypeB: MMR defects in Msh6TD mutant cell extracts. DNA mismatch repair activity
(Figures 7G–7J). In Msh6TD/TD mice, 5 of 9 (5/9) tumors analyzedwas assayed in Msh6TD/TD, Msh6TD/, and Msh6/ cell extracts as described
(Thomas et al., 1995). Substrates designated with a  contain the number were unstable at D7Mit91, 3/9 tumors were unstable at
of extra nucleotides that accompany the symbol. Substrates are designated D17Mit123, and 7/9 tumors were unstable at U12235. A similar
3 or 5, indicating the position of the nick relative to the mismatch. analysis in Msh6TD/ mice showed that 2/5 tumors were unstable
at D7Mit91, 1/5 tumors at D17Mit123, and 1/5 tumors at
U12235.
Survival and cancer phenotype in Msh6TD mutant mice
DNA damage response in Msh6TD/TD MEF cellsTo study survival and cancer susceptibility, we followed a cohort
Numerous studies have indicated that MMR not only repairsof Msh6TD mutant mice for a period of up to 24 months. The
mismatched bases, but also mediates an apoptotic responseMsh6TD/TD mice had a significantly reduced survival compared
after exposure of cells to DNA damaging agents (Buermeyer etto Msh6TD/ or wild-type mice (p values  0.0001; log rank test)
al., 1999; Li, 1999; Modrich, 1997). In addition, tumor cell lines(Figure 6). The 50% survival of Msh6TD/TD mice was at 12 months
or mouse cell lines that are deficient in either MSH2 or MSH6of age, and all of the mice died by 20 months of age. Although the
display increased resistance to the cytotoxic effect of a varietyoverall reduction in survival of Msh6TD/TD mice was comparable to
of genotoxic agents (de Wind et al., 1999; Drummond et al.,Msh6/ mice (p  0.91), there was a significant difference in
1995; Fink et al., 1997; Umar et al., 1997; Zhang et al., 1999).survival during the first 10 months of life. At this age, more than
To study the effect of the Msh6TD mutation on this MMR function,80% of Msh6TD/TD mice were still alive compared to only 60% of
we established Msh6/, Msh6/, and Msh6TD/TD MEF strainsMsh6/ mice (p  0.05). There was also a significant reduction
and analyzed their response to exposure to several DNA damag-in the survival of Msh6TD/ mice compared to their wild-type
ing agents. Msh6/ cells were resistant to the genotoxic effectslittermates (p  0.004). While 50% of the Msh6TD/ mice died
of cisplatin at the drug levels tested. In contrast, Msh6TD/TD cellsby 20 months of age, more than 80% of wild-type mice were
were as sensitive to cisplatin treatment as Msh6/ cells (Figuresstill alive.
8A and 8B). The difference in cisplatin sensitivity betweenThe reduction in survival in Msh6TD/TD mice was caused by
Msh6/ and Msh6/ or Msh6TD/TD cells was highly significantincreased cancer susceptibility. To examine the types of tumors
present in the Msh6TD/TD mutant mice, we analyzed the tumor (p  0.0001). Similarly, Msh6/ cells were largely resistant to
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Figure 4. MSI in genomic DNA of Msh6 mutant
mice
A: Genomic DNA from wild-type (Msh6/), Msh6
null (Msh6/), and Msh6TD homozygous mutant
mice (Msh6TD/TD) was analyzed for MSI at marker
D7Mit91. Asterisks indicate unstable alleles.
B: Comparison of MSI in Msh6 mutant mouse lines.
treatment with MNNG or 6-TG, while Msh6TD/TD cells remained those caused by the yeast mutation. The mouse Thr1217Asp
amino acid substitution resulted in an MSH2-MSH6 complexas sensitive to treatment with these agents as Msh6/ cells
(Figures 8D and 8E and Figures 8G and 8H, respectively). Fur- that could bind mispaired bases but was resistant to ATP-
induced release. In vitro, the homozygous mutation resulted inthermore, the sensitivity of the Msh6/ and Msh6TD/TD cells to all
three DNA-damaging agents was associated with a significant a defect in the repair of dinucleotide insertion/deletion mispairs,
in contrast to an Msh6 deletion mutation, which does not causeincrease in the number of apoptotic cells as compared to un-
treated cells (p values  0.0001) (Figures 8C, 8F, and 8I). In such defects. In addition, in normal mouse tissues, the homozy-
gous Msh6TD mutation caused both dinucleotide repeat instabil-contrast, no significant increase in the number of apoptotic cells
was seen with Msh6/ cells under these conditions. These ity and increased frameshift mutations in a reporter transgene,
in contrast to the weaker mutator phenotype caused by an Msh6results indicate that although the Msh6TD mutation causes DNA
repair deficiency, it does not affect the apoptotic response to deletion mutation. Normal tissues that were heterozygous for
the Msh6TD mutation also showed increased MSI and accumula-DNA damage.
tion of mutations in the reporter transgene. The homozygous
mutant Msh6TD mice had a cancer susceptibility phenotypeDiscussion
which was similar to that caused by an Msh6 deletion mutation,
except that the tumors showed dinucleotide repeat instabilityPrevious studies in yeast have defined a number of novel domi-
nant missense mutations in MSH6 that cause a stronger mutator in contrast to an absence of dinucleotide repeat instability in
tumors from Msh6 deletion mutant animals (Edelmann et al.,phenotype than deletion of MSH6 (Das Gupta and Kolodner,
2000). We have investigated whether the equivalent of one such 1997). Importantly, the heterozygous Msh6TD missense mutant
mice had significantly increased cancer susceptibility predictedmutation, resulting in the amino acid substitution Thr1217Asp,
would be dominant in the mouse, and what the phenotypic to result from a dominant mutation. Consistent with this, a hu-
man MSH6 mutation resulting in the substitution of Ile at theconsequences of such a mutation might be. Extensive analysis
of both ES cells and normal mouse tissues containing this muta- equivalent amino acid reported in a suspected HNPCC case
associated with dinucleotide repeat instability was a dominanttion indicate that it causes dominant defects in MMR similar to
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Figure 5. Increased mutation frequencies in Msh6 mutant mice
A: Comparison of mutation frequencies at the cII locus in Msh6 mutant
mice.
B: Comparison of cII mutation spectra in Msh6 mutant mice.
Figure 7. Tumors in Msh6TD mutant mice
A: Section of mesenteric lymphoma in an Msh6TD/TD mouse. Histologically it
was classified as diffuse non-Hodgkin’s lymphoma, mixed large noncleaved
and cleaved cell type. (200	).
mutation when modeled in yeast. These results illustrate the B: Section of mesenteric lymphoma stained with a B cell-specific antibody
complementary insights that can be obtained through the analy- (400	).
C: Adenoma in the small intestine of an Msh6TD/TD mouse. Histological featuressis of yeast, mouse, and human systems.
showed that the tumor was composed of glandular structures (40	).The analysis of microsatellite instability in human tumors
D: Section of intestinal tumor in an Msh6TD/TD mouse stained with an Msh6
indicates that in contrast to tumors with MSH2 or MLH1 muta- specific monoclonal antibody. The Msh6 protein expression was mostly de-
tions, mutations in MSH6 are often associated with a low micro- tected in nuclei of tumor cells (400	).
E: Section of intestinal tumor in an Msh3/ mouse stained with an Msh3satellite instability phenotype (MSI-L) at dinucleotide markers
specific monoclonal antibody. The Msh3 protein expression was absent in
tumor cells (400	).
F: Section of intestinal tumor in an Msh6TD/TD mouse stained with an Msh3
specific monoclonal antibody. The Msh3 protein expression was mostly de-
tected in the nuclei of tumor cells (400	).
G and H: MSI at dinucleotide marker D7Mit91 in an Msh6TD/TD GI adenoma
(G) and an Msh6TD/ lymphoma (H).
I and J: MSI at mononucleotide marker U12235 in an Msh6TD/TD GI adenoma
(I) and an Msh6TD/TD lymphoma (J).
(Akiyama et al., 1997; Kolodner et al., 1999; Verma et al., 1999;
Wijnen et al., 1999; Wu et al., 1999). However, in recent studies
of suspected HNPCC cases with MSH6 missense mutations,
several tumors have been identified that display high microsatel-
lite instability (MSI-H) (Berends et al., 2002). Our studies with
Msh6/ and Msh6TD/TD mutant mice provide an explanation for
Figure 6. Reduced survival of Msh6TD mutant mice these differences and indicate a genotype-phenotype correla-
The time of death or the time when the mice became moribund was tion for this type of genetic instability in MSH6 mutant tumor
recorded. The survival curves were generated by using GraphPad Prism 3.0 cells. In Msh6/ tumors, the lack of Msh6 protein does notsoftware. Statistical analysis was performed according to log-rank test. Solid
interfere with the function of the Msh2-Msh3 heterodimer, whilegreen line, Msh6/ mice (n  25); solid blue line, Msh6TD/ mice (n  29);
solid red line, Msh6TD/TD mice (n  25); solid black line, Msh6/ mice (n  25). the presence of the mutant Msh6TD protein in tumor cells appar-
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Figure 8. Drug sensitivity and apoptosis in Msh6
mutant cells
MEF strains of the different Msh6 genotypes were
exposed to cisplatin, MNNG, and 6-TG at varying
concentrations and for different time periods.
A: Survival of cells after 48 hr exposure at different
cisplatin concentrations.
B: Survival of cells after exposure to 80 
M cis-
platin at different time intervals.
C: Apoptotic response to cisplatin treatment (20

M cisplatin for 24 hr).
D: Survival of cells after 48 hr exposure at different
MNNG concentrations.
E: Survival of cells after exposure with 1.0 
g/ml
MNNG at different time intervals.
F: Apoptotic response to MNNG treatment (1.0

g/ml MNNG for 24 hr).
G: Survival of cells after 72 hr exposure at different
6-TG concentrations.
H: Survival of cells after exposure with 20 
M 6-TG
at different time intervals.
I: Apoptotic response to 6-TG treatment (10 
M
6-TG for 24 hr).
ently interferes with the Msh2-Msh3 mediated repair of dinucle- tions is the processing of DNA damage and the subsequent
induction of an apoptotic response. As a consequence, mam-otide insertion/deletion mutations, paralleling the impairment of
the repair of insertion/deletions in nuclear extracts. This predicts malian cells deficient in MSH2, MSH6, MLH1, and PMS2 display
resistance to DNA-damaging agents such as 6-TG, cisplatin,that in Msh6 mutant tumors that display an MSI-H phenotype,
the mutant Msh6 protein will be retained. In addition, loss of and MNNG (Buermeyer et al., 1999; de Wind et al., 1999; Drum-
mond et al., 1995; Duckett et al., 1996; Fink et al., 1997; Fishel,MSH3 protein is not required for the MSI phenotype. Indeed,
we observed that all of the tumors tested in the mouse remained 2001; Koi et al., 1994; Li, 1999; Modrich, 1997; Umar et al.,
1997). Complementation by chromosome transfer of MSH2,positive for Msh6 and Msh3 immunostaining. Our results are
consistent with a recent study of MSH6 tumors in human MSH6, and MLH1 reversed the resistance phenotype in mam-
malian cells and clearly implicated the MMR system in thisHNPCC and HNPCC-like patients that documented MSI-H colo-
rectal and endometrial tumors that were positive for MSH6 response (Koi et al., 1994; Umar et al., 1997). Because the
Msh2-Msh6 complex recognizes DNA adducts such as O6-staining and MSI-L tumors that were negative for MSH6 stain-
ing (Berends et al., 2002). Furthermore, the human MSH6 methylguanine and cisplatin adducts, it has been suggested
that MMR proteins may act in sensing DNA damage and alsoThr1219Ile mutation found to be a dominant mutation in yeast
was identified in a suspect HNPCC case with an MSI-H tumor. directly participate in the processing of damaged DNA residues
(Fishel, 2001; Li, 1999; Modrich, 1997). Several different modelsIt is therefore likely that the MSI phenotype in MSH6 mutant
tumors is a function of the type of MSH6 mutation and the have been developed to explain the role of MMR proteins in
DNA damage responses. In one model, DNA repair-competentstability of the mutant MSH6 protein present in the tumor cells.
It should be noted that in cases where MSH6 is not expressed, cells engage in futile repair cycles after treatment with alkylating
agents, and these futile repair cycles lead to the formation ofan MSI-H phenotype can occur due to a secondary mutation
in MSH3, a phenomenon seen in both yeast and a small number double strand breaks that signal cell cycle arrest and apoptosis
(Karran and Bignami, 1994). Alternatively, it has been suggestedof suspected HNPCC cases (Akiyama et al., 1997; Marsischky
et al., 1996; Sia et al., 1997). that MMR proteins may function as damage sensors directly
linked to apoptotic responses via a signal transduction cascadeOther important roles for MMR in addition to the correction
of mispaired bases have been recognized. One of these func- or indirectly linked by binding to damaged bases, which subse-
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quently blocks DNA replication or other processes, such as therapeutic agents. Therefore, determining the genotype/phe-
notype correlations of MSH6 missense mutations may providetranscription and repair, leading to cell death (Fishel, 2001; Li,
1999; Modrich, 1997). The finding that the mutant Msh2-Msh6TD valuable information for prevention, treatment, and prognosis
of individuals with such mutations.complex does not function in MMR but is still capable of mis-
match binding and of initiating apoptosis in response to cis-
Experimental proceduresplatin, MNNG, and 6-TG exposure supports the idea that Msh2-
Msh6 complexes can function as DNA damage sensors and
Yeast procedures
suggest that excision of DNA lesions is not required for the DNA All yeast genetics methods have been described in detail (Amin et al., 2001;
damage response function of MMR. Das Gupta and Kolodner, 2000; Marsischky et al., 1996). Yeast cells were
While it is generally accepted that an increase in mutation grown in YEPD or synthetic dropout (SD) medium with or without 2% bac-
toagar. SD medium was supplemented with the appropriate dropout mix ofrate due to MMR defects is an important factor underlying tu-
amino acids (BIO101, Inc., Vista, CA), and canavanine plates were SD argi-morigenesis, the importance of defects in MMR-mediated DNA
nine medium supplemented with 60 mg/l of canavanine (SIGMA, St. Louis,damage-induced apoptosis remains unclear. It has been pro-
MO). Transformations were performed using standard procedures. Muta-
posed that mutations in MMR genes, which result in resistance tions were placed at the chromosomal MSH6 locus using standard pop-in,
to DNA damage-induced apoptosis, provide a selective advan- pop-out procedures, and then the MSH6 gene present in each strain was
tage in the initial stages of tumorigenesis (Fishel, 2001). In this amplified by PCR and sequenced to verify the presence of the desired
mutation and the lack of additional mutations. Patch tests to identify mutatormodel, inactivation of MMR and the resulting increased mutation
phenotypes were performed as described (Amin et al., 2001), and mutationrates accelerate tumorigenesis but are not the origin of it. The
rates were determined by fluctuation analysis using at least 14 independentobservation that Msh6/ ES cells, but not Msh3/ ES cells,
cultures as described (Amin et al., 2001; Das Gupta and Kolodner, 2000;display resistance to MNNG is consistent with the unique
Lea and Coulson, 1948; Marsischky et al., 1996).
involvement of Msh2-Msh6 (but not Msh2-Msh3) in DNA dam- The yeast strains used in patch tests were isogenic derivatives of S288C
age response (de Wind et al., 1999), and it was suggested (Amin et al., 2001). The wild-type strain was RDKY 3686 MAT ura3-52
leu21 trp163 his3200 hom3-10 lys2::InsE-A10, and the msh3 msh6 dou-that this difference in function may explain the prevalence of
ble mutant was a derivative RDKY 4234 that also contained the msh6::hisGmutations in MSH2 and MSH6 but not MSH3 in HNPCC tumors
msh3::hisG mutations (Marsischky et al., 1996). The strain background(Heinen et al., 2002). In addition, it was suggested that the tissue
used for analysis of the effect of chromosomal msh6 mutations on mutationselectivity of HNPCC tumors might be traced to exposure to
rates is RDKY 2311 MATa trp1 ura3-52 ade2-1 hom3-10 leu2-3112. RDKY
certain types of DNA damaging processes such as alkylation 2311 and the mutant derivatives RDKY 3519 msh6::hisG and RDKY 3660
or oxidation in target tissues (Fishel, 2001). The analysis of msh6-G1067D have been described (Das Gupta and Kolodner, 2000). The
Msh6/ and Msh6TD/TD mice indicates that the apparently normal derivatives RDKY 5054 msh6-G1067T and RDKY 5022 msh6-G1067I were
constructed for this study using URA3 integrative plasmids containing theDNA damage response in Msh6TD/TD mutant mice did delay the
msh6-G1067T and msh6-G1067I mutations, respectively.onset of tumorigenesis during the first 10 months of life. How-
The plasmids used were constructed as follows. pRS315 is a standardever, it did not alter either the overall survival or tumor spectrum
ARS CEN LEU2 cloning vector, and pRDK439 is a derivative from our lab
of Msh6TD/TD mice as compared to Msh6/ mice. This suggests collection containing a genomic MSH6 fragment spanning the BamHI site
that the increased mutator phenotype in the mice is sufficient upstream of the MSH6 promoter to the first HindIII site downstream of MSH6
to drive tumorigenesis regardless of the status in DNA damage inserted into BamHI, HindIII-cut pRS315 (Das Gupta and Kolodner, 2000).
The msh6-G1067T and msh6-G1067I mutations were introduced with theresponse function. In a similar analysis of mice with an Msh2G674A
QuickChange Site-Directed Mutagenesis kit (Stratagene), and the resultingmissense mutation, which were MMR-deficient but retained
plasmids were fully sequenced. URA3 integrative plasmid derivatives werenormal apoptotic signaling, we also observed a strong cancer
then constructed by subcloning the BamHI, HindIII fragment into pRS306.phenotype (Lin et al., 2004). Like the Msh6TD/TD mice, the
Msh2G674A/G674A mice also showed a delayed tumor onset as com- Generation of Msh6TD mutant mice
pared to Msh2/ mice, suggesting that the DNA damage re- A 10 kb EcoRI fragment containing the Msh6 region surrounding exon 8
was isolated from a 129SvEv BAC genomic library and subcloned into pBlue-sponse function in these mice could inhibit tumorigenesis at an
script. A mutation was introduced that changed codon 1217 from threonineearly stage. However, the age of tumor onset of both Msh6TD/TD
(ACC) to aspartic acid (GAT) by site-directed mutagenesis (Stratagene Quickand Msh6/ mice is delayed compared to Msh2/ and
Change Kit) and verified by sequencing. A 5.0 kb NotI fragment containingMsh2G674A/G674A mice, which is possibly due to a stronger mutator
two loxP sites flanking a neomycin-PGKhygromycin resistance cassette was
phenotype in the Msh2 mutant mice. A similar relative mutator sublconed into a single Bsu36I site in intron 7. The targeting vector was
phenotype is seen in yeast (Das Gupta and Kolodner, 2000). linearized by NotI restriction digestion and electroporated into WW6 embry-
Based on these studies in mice, it seems likely that the MMR onic stem cells (Edelmann et al., 1997). Four correctly targeted ES cell lines
were injected into C57BL/6J blastocysts. Male chimeras that resulted fromfunctions in DNA repair and apoptosis cooperate in tumor sup-
these injections were mated to C57BL/6J females and transmitted the mutantpression, but that the increase in mutation rates resulting from
allele through their germline. F1 males carrying the mutant allele were matedMMR defects is sufficient to drive tumorigenesis. Unfortunately,
to Zp3Cre transgenic females (C57BL/6J) to remove the resistance cassette
it has not yet been possible to identify mutations in MMR genes by LoxP-mediated recombination. Male and female mice carrying the modi-
that inactivate apoptosis but not DNA repair to evaluate whether fied allele were intercrossed to generate Msh6/, Msh6TD/, and Msh6TD/TD
defects in MMR-induced apoptosis also can drive tumorigene- mutant mice.
sis. One implication of the observation that MMR missense
RT-PCR analysismutations can differentially affect DNA repair and MMR-induced
Total RNA was isolated from Msh6TD mutant ES cell lines using the RNeasyapoptosis is that the clinical characteristics of HNPCC caused
purification Kit (Qiagen). RT-PCR was performed using forward primer: 5-by missense mutations may be more heterogeneous than those
AAGACAGGCTGGTCTGTTGG-3 and reverse primer: 5-GCTGTCCCAT
caused by complete loss of function mutations. In addition, CAAAAGTTGC-3 using the Titan One Tube-RT-PCR reaction kit (Roche)
human tumors with certain MSH6 missense mutations will dis- according to the manufacturers instruction. The resulting 246 bp fragment
was digested with SfaNI to detect the presence of the mutant RNA transcript.play MSI and may remain responsive to treatment with chemo-
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Western blot analysis was calculated as (treated cells/untreated cells) 	 100. The apoptotic re-
MEF cell extracts were prepared according to standard procedures, and 50 sponse to drug exposure was measured by TUNEL (DeadEnd Fluorometric

g protein of each cell lysate was separated on a 10% SDS-PAGE gel. TUNEL System, Promega). All experiments were performed for three different
Protein was transferred onto PROTRAN membranes, and the membranes MEF strains for each Msh6 genotype and repeated at least three times
were subsequently incubated with monoclonal antibodies directed against for each strain. Cisplatin (Bedford Laboratories), 6-TG (Sigma), and MNNG
Msh2 (Ab-2, Oncogene), Msh6 (clone 44, BD Biosciences), and rabbit poly- (Sigma) dilutions in culture medium were prepared fresh before use. For the
clonal antibody directed against -tubulin (H-235, Santa Cruz). exposure to MNNG, 20 
M O6-benzylguanine (Sigma) was added to the
medium.
Gel mobility shift assays
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